FY2030 Earnings Forecast for enGene Issued By HC Wainwright

enGene Holdings Inc. (NASDAQ:ENGN) – Stock analysts at HC Wainwright raised their FY2030 earnings estimates for shares of enGene in a research note issued on Monday, March 9th. HC Wainwright analyst A. Maldonado now expects that the company will earn $0.70 per share for the year, up from their prior estimate of $0.61. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for enGene’s current full-year earnings is ($1.56) per share.

Several other brokerages also recently weighed in on ENGN. Citigroup reiterated a “market outperform” rating on shares of enGene in a report on Monday, January 5th. Oppenheimer reduced their target price on enGene from $33.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday. UBS Group lifted their price target on enGene from $4.00 to $10.00 and gave the company a “neutral” rating in a report on Wednesday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of enGene in a report on Friday, January 9th. Finally, Jefferies Financial Group assumed coverage on shares of enGene in a research report on Friday, January 30th. They set a “buy” rating and a $28.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.86.

enGene Stock Performance

Shares of ENGN opened at $6.88 on Wednesday. enGene has a 1 year low of $2.65 and a 1 year high of $12.25. The company’s 50 day simple moving average is $9.46 and its 200 day simple moving average is $8.10. The company has a market capitalization of $460.89 million, a price-to-earnings ratio of -3.06 and a beta of -0.29. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.30 and a current ratio of 11.75.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.11.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Affinity Asset Advisors LLC acquired a new position in shares of enGene during the 2nd quarter valued at $280,000. Elmind Capital LP purchased a new position in enGene in the fourth quarter valued at about $1,896,000. Eversept Partners LP acquired a new position in shares of enGene during the fourth quarter worth about $4,116,000. Cormorant Asset Management LP boosted its position in shares of enGene by 72.1% in the fourth quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock worth $36,120,000 after buying an additional 1,676,405 shares during the period. Finally, Omega Fund Management LLC grew its stake in shares of enGene by 66.5% in the fourth quarter. Omega Fund Management LLC now owns 876,357 shares of the company’s stock valued at $7,914,000 after buying an additional 350,000 shares in the last quarter. Hedge funds and other institutional investors own 64.16% of the company’s stock.

Key Headlines Impacting enGene

Here are the key news stories impacting enGene this week:

• Positive Sentiment: HC Wainwright raised its FY2030 EPS forecast to $0.70 (from $0.61) and reiterated a “Buy” rating with a $25 price objective — this signals improved long-term profitability expectations and continued analyst conviction. enGene (NASDAQ:ENGN) Earns Buy Rating from HC Wainwright
• Positive Sentiment: enGene reported Q4 results of ($0.44) EPS vs. consensus ($0.55), beating estimates by $0.11 — an earnings beat that can support the stock and investor confidence. View Press Release
• Positive Sentiment: Short interest declined 17.7% in February to ~1.24M shares (about 2.1% of shares), reducing some near-term bearish pressure despite a still-elevated days-to-cover (~10.4 days).
• Neutral Sentiment: Oppenheimer trimmed its price target from $33 to $30 but kept an “Outperform” rating — a modest pullback in upside expectations while retaining a bullish stance; investors may view this as mixed. Oppenheimer Lowers enGene Price Target
• Neutral Sentiment: Management presented at the Barclays 28th Annual Global Healthcare Conference; the transcript provides additional pipeline and strategy detail but no material new disclosures were flagged in headlines. enGene Presents at Barclays — Transcript
• Neutral Sentiment: One March short-interest report shows 0 shares (with NaN change) — likely a data/reporting anomaly rather than a substantive market shift.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.